Literature DB >> 9278394

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

M Besancon1, A Simon, G Sachs, J M Shin.   

Abstract

The vesicular gastric H,K-ATPase catalyzes an electroneutral H for K exchange allowing acidification of the intravesicular space. There is a total of 28 cysteines present in the alpha subunit of the gastric H,K-ATPase, of which 10 are found in the predicted transmembrane segments and their connecting loop, and 9 are present in the beta subunit, of which 6 are disulfide-linked. To determine which of these was accessible to extracytoplasmic attack, the enzyme was inhibited by four different substituted 2-pyridylmethylsulfinyl benzimidazoles, 5-methoxy-2-[(4-methoxy-3, 5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole (omeprazole), 2-[(4-trifluoroethoxy-3-methyl-2-pyridyl)methylsulfinyl]-1H-ben zimida zole (lansoprazole), 5-difluoromethoxy-2-[3, 4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole (pantoprazole), and 2-[(4-(3-methoxypropoxy)-3-methyl)-2-pyridyl)methylsulfinyl]-1H-++ +benzi midazole (rabeprazole), under acid transporting conditions. All of these compounds are weak bases that accumulate in the acidic space generated by the pump and undergo an acid catalyzed rearrangement to a cationic sulfenamide, which forms disulfides with accessible cysteines. The relative rates of acid activation of these compounds corresponded to the relative rates of inhibition of ATPase activity and acid transport. Fragmentation of the enzyme by trypsin followed by SDS-polyacrylamide gel electrophoresis showed that omeprazole bound covalently to one of the two cysteines in the domains containing the fifth and sixth transmembrane segments and their extracytoplasmic loop and to cysteine 892 in the loop between the seventh and eighth transmembrane segments, but inhibition correlated with the reaction with cysteines in the fifth and sixth domain. Lansoprazole bound to the cysteines in these two domains as well as to cysteine 321 toward the extracytoplasmic end of the third transmembrane segments. Pantoprazole bound only to either cysteine 813 or 822 in the fifth and sixth transmembrane region. The inhibition of Rabeprazole correlated also with its binding to this part of the protein, but this compound continued to bind after full inhibition, eventually binding also to cysteines 321 and 892. No binding was found to any of the cysteines in the seventh to tenth transmembrane segments. Thermolysin digestion of the isolated omeprazole-labeled fifth and sixth transmembrane pair showed that cysteine 813 was the site of labeling. It is concluded that binding of these sided reagents to cysteine 813 in the loop between transmembrane (TM)5 and TM6 is sufficient for inhibition of ATPase activity and acid transport by the gastric acid pump. Of the 10 cysteines present in the membrane and extracytoplasmic domain, only three are exposed sufficiently to allow reactivity with these cationic thiol reagents. The binding to cysteine 813 defines the location of the extracytoplasmic loop between TM5 and TM6 and places the carboxylic acids 820 and 824 conserved between the gastric H,K- and the Na,K-ATPases in TM6, consistent with their assumed role in cation binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9278394     DOI: 10.1074/jbc.272.36.22438

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  Rabeprazole: quest for the best PPI.

Authors:  Kentaro Sugano
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

Review 2.  Structural similarities of Na,K-ATPase and SERCA, the Ca(2+)-ATPase of the sarcoplasmic reticulum.

Authors:  K J Sweadner; C Donnet
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 3.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

4.  Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Authors:  Hank S Wang; David S Oh; Ariana Anderson; Jose Nieto; Phuong Tien; Gordon Ohning; Joseph R Pisegna
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

5.  Study of the pharmacokinetics and intragastric pH of rabeprazole given as successive intravenous infusion to healthy Chinese volunteers.

Authors:  Yongqing Wang; Yaozong Yuan; Ling Meng; Hongwei Fan; Jianming Xu; Hongwen Zhang; Meifeng Wang; Hongyu Yuan; Ning Ou; Haibo Zhang; Yang Chao; Ruihua Shi
Journal:  Eur J Clin Pharmacol       Date:  2010-11-26       Impact factor: 2.953

Review 6.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

7.  Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype.

Authors:  Takashi Ando; Takeshi Ishikawa; Satoshi Kokura; Yuji Naito; Norimasa Yoshida; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

8.  Analysis of the gastric H,K ATPase for ion pathways and inhibitor binding sites.

Authors:  Keith Munson; Richard J Law; George Sachs
Journal:  Biochemistry       Date:  2007-04-11       Impact factor: 3.162

9.  Quadruple therapy for eradication of Helicobacter pylori.

Authors:  Hai-Jun Ma; Jin-Liang Wang
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

10.  Benzimidazole covalent probes and the gastric H(+)/K(+)-ATPase as a model system for protein labeling in a copper-free setting.

Authors:  Chelsea J Paresi; Qi Liu; Yue-Ming Li
Journal:  Mol Biosyst       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.